clear cell renal cell carcinoma (Cancer)
Information
- Disease name
- clear cell renal cell carcinoma
- Disease ID
- DOID:4467
- Description
- "A renal cell carcinoma that has_material_basis_in cells that appear very pale or clear when examined under microscope." [url:http\://www.cancer.gov/dictionary?CdrID=45063, url:https\://cancergenome.nih.gov/cancersselected/kidneyclearcell]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03284385 | Active, not recruiting | Phase 2 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | January 29, 2019 | August 30, 2024 |
| NCT01038778 | Active, not recruiting | Phase 1/Phase 2 | Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | October 29, 2009 | July 17, 2024 |
| NCT02496208 | Active, not recruiting | Phase 1 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | July 22, 2015 | September 30, 2024 |
| NCT02293980 | Active, not recruiting | Phase 1 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | November 25, 2014 | November 30, 2026 |
| NCT03829111 | Active, not recruiting | Phase 1 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | May 14, 2019 | June 11, 2024 |
| NCT03793166 | Active, not recruiting | Phase 3 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | June 7, 2019 | September 15, 2024 |
| NCT01575548 | Active, not recruiting | Phase 3 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | August 8, 2012 | February 22, 2025 |
| NCT05663710 | Active, not recruiting | Phase 1/Phase 2 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | June 30, 2023 | October 30, 2027 |
| NCT05199272 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | December 29, 2021 | March 2025 |
| NCT04022343 | Active, not recruiting | Phase 2 | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | August 6, 2019 | May 25, 2025 |
| NCT04627064 | Active, not recruiting | Phase 1 | ABEMA Alone or in COMBO With MK-6482 | December 31, 2020 | December 31, 2025 |
| NCT03473730 | Active, not recruiting | Early Phase 1 | Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | May 29, 2018 | June 30, 2024 |
| NCT03308396 | Active, not recruiting | Phase 1/Phase 2 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | December 19, 2017 | December 2023 |
| NCT02974738 | Active, not recruiting | Phase 1 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | December 7, 2016 | April 14, 2025 |
| NCT02210117 | Active, not recruiting | Early Phase 1 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | November 25, 2014 | November 30, 2025 |
| NCT03092856 | Active, not recruiting | Phase 2 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | July 19, 2017 | July 19, 2025 |
| NCT01684397 | Active, not recruiting | Phase 1/Phase 2 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | November 21, 2012 | January 2, 2025 |
| NCT06090331 | Available | 89Zr-DFO-girentuximab Expanded Access Program (EAP) | |||
| NCT00602862 | Completed | N/A | Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 | July 2007 | June 2012 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT05728515 | Completed | Early Phase 1 | A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma | December 25, 2021 | March 4, 2022 |
| NCT01141569 | Completed | Phase 2 | A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy | June 2010 | December 2013 |
| NCT01157091 | Completed | Phase 2 | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer | December 8, 2010 | December 31, 2013 |
| NCT01158222 | Completed | Phase 2 | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer | August 18, 2010 | February 1, 2017 |
| NCT01158521 | Completed | Phase 2 | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | June 2010 | January 2016 |
| NCT01243359 | Completed | Phase 1 | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | October 2010 | |
| NCT01497821 | Completed | Phase 1 | AMG 172 First in Human Study in Patients With Kidney Cancer | January 2012 | January 2015 |
| NCT05432947 | Completed | N/A | 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients | April 14, 2022 | September 15, 2022 |
| NCT01727089 | Completed | Phase 2 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | November 1, 2012 | August 8, 2017 |
| NCT04496089 | Completed | Phase 1 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC | August 1, 2020 | April 6, 2021 |
| NCT01826877 | Completed | Phase 1 | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer | January 14, 2013 | May 27, 2021 |
| NCT01835158 | Completed | Phase 2 | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | July 8, 2013 | |
| NCT04169711 | Completed | Phase 1 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | August 17, 2020 | July 22, 2022 |
| NCT02118337 | Completed | Phase 1/Phase 2 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | May 19, 2014 | March 17, 2020 |
| NCT02247583 | Completed | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment | February 2011 | July 2013 | |
| NCT03849118 | Completed | Phase 3 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study | August 15, 2019 | November 7, 2022 |
| NCT02575222 | Completed | Phase 1 | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | February 2016 | June 9, 2020 |
| NCT02607553 | Completed | Phase 2 | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | June 2016 | February 2017 |
| NCT02626130 | Completed | Early Phase 1 | Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | March 30, 2016 | June 20, 2022 |
| NCT03680521 | Completed | Phase 2 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | October 10, 2018 | May 18, 2023 |
| NCT02667886 | Completed | Phase 1/Phase 2 | Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma | January 2016 | March 2022 |
| NCT03163667 | Completed | Phase 2 | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | September 6, 2017 | June 1, 2020 |
| NCT03015740 | Completed | Phase 1/Phase 2 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | April 23, 2017 | September 6, 2022 |
| NCT03108066 | Completed | Phase 2 | PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma | April 24, 2017 | September 27, 2023 |
| NCT02700568 | Completed | Phase 2 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors | January 2016 | August 2018 |
| NCT00027820 | Completed | Phase 1/Phase 2 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | August 2001 | September 5, 2004 |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT00005799 | Completed | N/A | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | November 1999 | |
| NCT00101114 | Completed | Phase 2 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | September 2004 | |
| NCT00112840 | Completed | Phase 1/Phase 2 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | May 2005 | September 10, 2015 |
| NCT00126503 | Completed | Phase 1/Phase 2 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | May 2005 | February 2012 |
| NCT00126594 | Completed | Phase 2 | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | June 2005 | August 2013 |
| NCT00182702 | Completed | Phase 2 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | July 2005 | |
| NCT00193258 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | June 2004 | August 2011 |
| NCT00199888 | Completed | Phase 1 | Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. | June 2005 | May 29, 2009 |
| NCT05861778 | Completed | Phase 1 | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma | June 26, 2023 | November 27, 2023 |
| NCT00324870 | Completed | Phase 1/Phase 2 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | February 2006 | November 2013 |
| NCT00326898 | Completed | Phase 3 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | April 24, 2006 | September 1, 2021 |
| NCT00335556 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | June 2006 | |
| NCT00378703 | Completed | Phase 2 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | September 14, 2007 | March 21, 2017 |
| NCT00408902 | Completed | Phase 2 | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer | November 2006 | December 2008 |
| NCT00499135 | Completed | Phase 1 | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | May 22, 2007 | May 14, 2014 |
| NCT06447103 | Not yet recruiting | Phase 2 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | June 1, 2024 | June 1, 2030 |
| NCT04958473 | Not yet recruiting | Phase 2 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer | August 1, 2021 | August 1, 2025 |
| NCT05119335 | Recruiting | Phase 1/Phase 2 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | October 26, 2021 | September 2026 |
| NCT06138496 | Recruiting | Phase 2 | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | September 1, 2023 | December 31, 2025 |
| NCT05214885 | Recruiting | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | February 11, 2022 | December 31, 2026 | |
| NCT05239533 | Recruiting | Phase 2 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | February 16, 2022 | March 2025 |
| NCT05286294 | Recruiting | Phase 2 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders | June 28, 2022 | December 31, 2034 |
| NCT05363631 | Recruiting | Phase 1/Phase 2 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | September 19, 2022 | December 31, 2026 |
| NCT04006405 | Recruiting | AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC | January 10, 2020 | February 2025 | |
| NCT05433142 | Recruiting | Phase 1 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | June 13, 2022 | March 2027 |
| NCT05520099 | Recruiting | Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | June 26, 2023 | January 2027 | |
| NCT05536141 | Recruiting | Phase 1 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | October 26, 2022 | January 2026 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT06088134 | Recruiting | Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC) | September 1, 2022 | August 1, 2024 | |
| NCT05879510 | Recruiting | Phase 2 | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | August 1, 2023 | July 1, 2025 |
| NCT05795595 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | March 13, 2023 | May 2030 |
| NCT04053855 | Recruiting | Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma | January 29, 2020 | August 2024 | |
| NCT05879497 | Recruiting | Phase 2 | 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion | August 1, 2023 | July 1, 2025 |
| NCT04071223 | Recruiting | Phase 2 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | July 29, 2020 | October 1, 2024 |
| NCT06242470 | Recruiting | Phase 1 | A Study of MGC026 in Participants With Advanced Solid Tumors | March 6, 2024 | October 2028 |
| NCT06339138 | Recruiting | Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | February 20, 2018 | January 31, 2027 | |
| NCT04370509 | Recruiting | Phase 2 | Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery | February 9, 2021 | September 1, 2025 |
| NCT04374877 | Recruiting | Phase 1 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | April 22, 2020 | August 2026 |
| NCT06052852 | Recruiting | Phase 1/Phase 2 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | October 11, 2023 | March 2028 |
| NCT06049576 | Recruiting | Phase 1 | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | October 6, 2023 | March 14, 2026 |
| NCT03682289 | Recruiting | Phase 2 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | January 17, 2019 | July 31, 2025 |
| NCT04810078 | Recruiting | Phase 3 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | May 24, 2021 | January 29, 2026 |
| NCT06195150 | Recruiting | Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer | November 8, 2023 | August 31, 2024 | |
| NCT04989959 | Recruiting | Phase 1 | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma | August 18, 2021 | August 18, 2026 |
| NCT05935748 | Recruiting | Phase 2 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | July 28, 2023 | September 2026 |
| NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
| NCT04779151 | Suspended | Phase 2 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab | April 7, 2021 | December 2027 |
| NCT03185182 | Terminated | Phase 2 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma | July 14, 2017 | September 12, 2018 |
| NCT02923531 | Terminated | Phase 1/Phase 2 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | December 7, 2016 | August 8, 2018 |
| NCT03334409 | Terminated | Phase 2 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | February 16, 2018 | March 13, 2021 |
| NCT02885649 | Terminated | Early Phase 1 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | December 5, 2017 | March 2, 2020 |
| NCT02628535 | Terminated | Phase 1 | Safety Study of MGD009 in B7-H3-expressing Tumors | September 2015 | November 25, 2019 |
| NCT02595918 | Terminated | Phase 1 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | May 19, 2016 | August 1, 2020 |
| NCT02581384 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | January 2017 | August 2020 |
| NCT03875313 | Terminated | Phase 1/Phase 2 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | May 20, 2019 | July 29, 2020 |
| NCT01943188 | Terminated | Phase 1 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer | May 2014 | |
| NCT04300140 | Terminated | Phase 1/Phase 2 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | February 26, 2021 | August 14, 2023 |
| NCT00098618 | Terminated | Phase 2 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | October 2004 | |
| NCT05121948 | Terminated | Phase 1 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | February 23, 2022 | March 1, 2024 |
| NCT01599832 | Terminated | N/A | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | June 2012 | December 2015 |
| NCT01582009 | Terminated | Phase 1/Phase 2 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | March 2010 | December 2015 |
| NCT01198158 | Terminated | Phase 3 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | September 15, 2010 | December 16, 2017 |
| NCT00303862 | Terminated | Phase 2 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | March 2006 | March 2011 |
| NCT00126659 | Terminated | Phase 2 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | January 2006 | December 2009 |
| NCT01069770 | Unknown status | Phase 2 | Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) | July 2009 | June 2012 |
| NCT03592199 | Unknown status | Phase 2 | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib | December 11, 2017 | December 11, 2022 |
| NCT03438708 | Unknown status | Phase 2 | Prior Axitinib as a Determinant of Outcome of Renal Surgery | March 5, 2018 | February 1, 2020 |
| NCT04995016 | Unknown status | Phase 2 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma | August 20, 2021 | August 20, 2023 |
| NCT01791387 | Unknown status | Phase 2 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC | March 2012 | June 2015 |
| NCT02022787 | Unknown status | Value of Various Chemokines in the Detection and Follow up of RCC | January 2014 | November 2016 | |
| NCT03987698 | Unknown status | Phase 2 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | June 1, 2019 | June 1, 2022 |
| NCT01642095 | Withdrawn | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | August 22, 2012 | ||
| NCT03149159 | Withdrawn | Phase 2 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | April 1, 2018 | April 1, 2018 |
| NCT02307474 | Withdrawn | N/A | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | September 2015 | September 2015 |
- Disase is a (Disease Ontology)
- DOID:4450
- Cross Reference ID (Disease Ontology)
- GARD:9574
- Cross Reference ID (Disease Ontology)
- MESH:D002292
- Cross Reference ID (Disease Ontology)
- NCI:C4033
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:254915003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279702
- Exact Synonym (Disease Ontology)
- Clear cell carcinoma of kidney
- Exact Synonym (Disease Ontology)
- clear cell kidney carcinoma
- Exact Synonym (Disease Ontology)
- conventional (Clear cell) renal cell carcinoma
- Exact Synonym (Disease Ontology)
- conventional renal cell carcinoma
- Exact Synonym (Disease Ontology)
- renal clear cell carcinoma
- Disase Synonym (Disease Ontology)
- Clear-cell metastatic renal cell carcinoma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006770